NVRO241220C30000
- 2.12
- 0.000.00%
Nevro Newsroom
Nevro's SI Joint Fixation System Delivers Enhanced Stability and Fusion for Patients
NVRO Stock Declines Despite Positive Study Data of Nevro1 System
New Study Demonstrates Multiple Advantages of Nevro1, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Stock May Gain on the CE Mark Certification for HFX IQ
Express News | Engaged Capital LLC Cuts Share Stake in Nevro Corp to 1.5% as of Nov 12 - SEC Filing
Express News | Nevro: Reaffirms Full-Year 2024 Revenue Guidance & Raises Full-Year 2024 Adjusted Ebitda Guidance
Engaged Capital Adds BlackLine, Exits Shake Shack, Others in Q3
Nevro Corp. (NYSE:NVRO) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Raises Target Price to $7
A Quick Look at Today's Ratings for Nevro(NVRO.US), With a Forecast Between $7 to $7
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Express News | Nevro Corp : Truist Securities Raises Target Price to $7 From $5.5
Nevro Secures CE Mark for AI-based Spinal Cord Stimulation System
Hold Rating for Nevro Corp Amid Revenue Growth Challenges and Market Uncertainty
Nevro Corp's Market Cap Challenges: Impairment Risks and Investor Concerns
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Why Medical Device Firm Nevro Stock Is Trading Higher On Tuesday
Peeling Back The Layers: Exploring Nevro Through Analyst Insights
Express News | JMP Securities Reiterates Market Perform on Nevro